Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
0.00 (0.00%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.17 - 4.36
52 week 3.78 - 10.06
Open 4.27
Vol / Avg. 1.34M/1.39M
Mkt cap 583.63M
P/E     -
Div/yield     -
EPS -0.30
Shares 136.68M
Beta 1.59
Inst. own 76%
Feb 23, 2017
Q4 2016 Achillion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -7.61%
Operating margin - -22.85%
EBITD margin - -21.80%
Return on average assets -19.62% -1.62%
Return on average equity -20.27% -1.70%
Employees 79 -
CDP Score - -


300 George St
NEW HAVEN, CT 06511-6624
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Officers and directors

David I. Scheer Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Mary Kay Fenton CPA Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Joel C. Barrish Ph.D. Executive Vice President, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Martha E. Manning Esq. Executive Vice President, General Counsel, Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
David Apelian M.D. Ph.D. Executive Vice President, Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Joseph Truitt Executive Vice President, Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Amy Jennings Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 66
Bio & Compensation  - Reuters
Frank A. G. M. Verwiel M.D. Director
Age: 55
Bio & Compensation  - Reuters